Contrast nephropathy: Risk factors and the role of beta blockers (Editorial Comment)

References (1)

1. Toprak O, Cirit M, Tanrısev M, Yazıcı C, Canoz O, Sipahioğlu M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008; 23: 853-9. [CrossRef] 2. Tublin ME, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy. AJR Am J Roentgenol 1998; 171: 933-9. [CrossRef] 3. Akgüllü Ç, Eryılmaz U, Güngör H, Huyut A, Zencir C, Hekim T. A clinical study about contrast nephropathy: risk factors and the role of beta blockers. Anatol J Cardiol 2015; 15: 232-40. 4. Funaki B. Contrast-induced nephropathy: What we know, what we think we know, and what we don’t know. Semin Intervent Radiol 2005; 22: 108-13. [CrossRef] 5. Shin DH, Choi DJ, Youn TJ, Yoon CH, Suh JW, Kim KI, et al. Comparison of contrast-induced nephrotoxicity of iodixanol and iopromide in patients with renal insufficiency undergoing coronary angiography. Am J Cardiol 2011; 108: 189-94. [CrossRef] 6. Friedewald WE, Goldfarb S, Laskey WK, Vetrovec GW, Roberts WC. The editor's roundtable: contrast agents and risk for contrast- induced nephropathy. Am J Cardiol 2011; 107: 1848-55. [CrossRef] 7. Bowden RG, La Bounty P, Shelmadine B, Beaujean AA, Wilson RL, Hebert S. Reverse epidemiology of lipid-death associations in a cohort of end-stage renal disease patients. Nephron Clin Pract 2011; 199: c214-c9. [CrossRef]